Trial Profile
TAS-102 and Bevacizumab as salvage line chemotherapy for colorectal cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 24 Mar 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 22 Mar 2022 Status changed from recruiting to discontinued.
- 20 Mar 2019 Status changed from not yet recruiting to recruiting.
- 21 Mar 2018 New trial record